Key facts
- UFraction8’s last known valuation is $8.7M (Feb 2025).
- It has raised $8.9M; the latest was Later Stage VC ($4.3M) in Feb 2025.
- Notable investors include Innovate UK, Creative Destruction Lab, EIT Food, Scottish Enterprise, Leave a Nest Capital — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for UFraction8
- ·The full record, as it builds
Funding rounds
No funding rounds for UFraction8 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About UFraction8
Developer of a scalable cell separation technology designed for new levels of throughput for multiplexed microfluidic devices. The company's technology is generated using various microfluidic-based devices to perform industrial-scale tasks such as liquid particle processing, cell separation, dewatering, and selective concentration of pathogens, enabling industries to save cost against three liquid processing technologies of filtration, flow centrifugation, and flocculation.
- Sector
- Healthcare
- HQ
- Falkirk, United Kingdom
- Founded
- 2017
- Employees
- 10
- Website
- ufraction8.com/
- Ownership
- Privately Held (backing)
UFraction8 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in UFraction8 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on UFraction8 in its N-PORT filings yet. We sweep new filings monthly.